secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organon & Co. (OGN)
CIK:        0001821825
Form:       8-K
Filed at:   2021-08-12T23:59:59+00:00
Accession:  0001104659-21-103773
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organon Q2 2021 revenue $1.6B, net income $431M; declares inaugural $0.28 quarterly dividend
--------------------------------------------------------------------------------

- Q2 2021 revenue $1,595M (+5% as-reported; -1% ex-FX); Women's Health +19%, Biosimilars +43%, Established Brands -4%.
- Net income from cont. ops. $431M ($1.70 diluted EPS); adjusted net income $437M ($1.72 adj. diluted EPS); adjusted EBITDA $627M.
- Board declares quarterly dividend of $0.28/share, payable Sept 13, 2021 to holders of record Aug 23, 2021.
- Full-year 2021 guidance affirmed: revenue $6.1B-$6.4B, adjusted EBITDA margin 36%-38%, interest ~$400M.
- Cash and equivalents $730M, debt $9,348M, net debt $8,618M as of June 30, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821825/000110465921103773/0001104659-21-103773-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821825/000110465921103773/tm2124441d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-103773

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer